Chemotherapy in gastric cancer: a review and updated meta-analysis.

Karl-Gunnar Janunger, Larsolof Hafström, Bengt Glimelius
{"title":"Chemotherapy in gastric cancer: a review and updated meta-analysis.","authors":"Karl-Gunnar Janunger,&nbsp;Larsolof Hafström,&nbsp;Bengt Glimelius","doi":"10.1080/11024150201680005","DOIUrl":null,"url":null,"abstract":"<p><strong>Unlabelled: </strong>The five years survival rate for patients with gastric cancer is 15-25%. With the aim of improving survival, chemotherapy has been used in different adjuvant settings. Similarly, but with the aim of improving quality of life and prolonging life, chemotherapy has been used extensively in metastatic disease. In this review we have included studies of systemic and intraperitoneal chemotherapy given before, during or after operation and for advanced disease. A meta-analysis has been made on the 21 randomised studies that used adjuvant systemic chemotherapy postoperatively. A significant survival benefit for the patients treated postoperatively compared with controls was identified (odds ratio (OR) 0.84, 95% confidence interval (CI) 0.74 to 0.96). When western and Asian studies were analysed separately we found no survival benefit for the treated patients in the western groups (OR 0.96 (95 CI 0.83 to 1.12)). Flaws in the conduct of several trials made it difficult to draw firm conclusions, including the exclusion of a small but clinically meaningful survival benefit. Preoperative or neoadjuvant chemotherapy has shown effects in some patients, but no significant benefit was found in the few randomised studies. The few studies that reported intraperitoneal therapy showed no detectable survival benefit either. In patients with advanced disease, four small randomised studies found significantly longer survival in the treated patients. The survival benefit is in the range of 3-9 months, and there were also improvements of the quality of life. Several drug combinations have been tested, however, with no confirmed superiority for a particular regimen.</p><p><strong>Conclusions: </strong>Adjuvant chemotherapy cannot be recommended as a routine because of the lack of confirmed beneficial effects. Some patients with advanced disease will have a clinically important benefit from palliative chemotherapy, so this can be recommended for patients who are otherwise in good health.</p>","PeriodicalId":22411,"journal":{"name":"The European journal of surgery = Acta chirurgica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"95","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The European journal of surgery = Acta chirurgica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/11024150201680005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 95

Abstract

Unlabelled: The five years survival rate for patients with gastric cancer is 15-25%. With the aim of improving survival, chemotherapy has been used in different adjuvant settings. Similarly, but with the aim of improving quality of life and prolonging life, chemotherapy has been used extensively in metastatic disease. In this review we have included studies of systemic and intraperitoneal chemotherapy given before, during or after operation and for advanced disease. A meta-analysis has been made on the 21 randomised studies that used adjuvant systemic chemotherapy postoperatively. A significant survival benefit for the patients treated postoperatively compared with controls was identified (odds ratio (OR) 0.84, 95% confidence interval (CI) 0.74 to 0.96). When western and Asian studies were analysed separately we found no survival benefit for the treated patients in the western groups (OR 0.96 (95 CI 0.83 to 1.12)). Flaws in the conduct of several trials made it difficult to draw firm conclusions, including the exclusion of a small but clinically meaningful survival benefit. Preoperative or neoadjuvant chemotherapy has shown effects in some patients, but no significant benefit was found in the few randomised studies. The few studies that reported intraperitoneal therapy showed no detectable survival benefit either. In patients with advanced disease, four small randomised studies found significantly longer survival in the treated patients. The survival benefit is in the range of 3-9 months, and there were also improvements of the quality of life. Several drug combinations have been tested, however, with no confirmed superiority for a particular regimen.

Conclusions: Adjuvant chemotherapy cannot be recommended as a routine because of the lack of confirmed beneficial effects. Some patients with advanced disease will have a clinically important benefit from palliative chemotherapy, so this can be recommended for patients who are otherwise in good health.

胃癌的化疗:综述和最新的荟萃分析。
未标记:胃癌患者的5年生存率为15-25%。为了提高生存率,化疗已被用于不同的辅助设置。同样,为了提高生活质量和延长生命,化疗已广泛用于转移性疾病。在这篇综述中,我们纳入了术前、术中或术后以及晚期疾病的全身和腹腔化疗的研究。一项荟萃分析对21项术后使用辅助全身化疗的随机研究进行了分析。与对照组相比,术后治疗的患者的生存期显著改善(优势比(OR) 0.84, 95%可信区间(CI) 0.74至0.96)。当分别分析西方和亚洲研究时,我们发现西方组治疗患者没有生存获益(OR 0.96 (95 CI 0.83至1.12))。几项试验中存在的缺陷使得很难得出确切的结论,包括排除了一个很小但临床上有意义的生存益处。术前或新辅助化疗在一些患者中显示出效果,但在少数随机研究中没有发现显著的益处。少数报告腹腔内治疗的研究也没有显示可检测到的生存益处。在晚期疾病患者中,四项小型随机研究发现,接受治疗的患者的生存期明显延长。生存期在3-9个月之间,生活质量也有所改善。然而,已经对几种药物组合进行了测试,没有证实某一特定方案具有优势。结论:由于缺乏证实的有益效果,辅助化疗不能作为常规推荐。一些晚期疾病患者将从姑息性化疗中获得重要的临床益处,因此可以推荐健康状况良好的患者进行姑息性化疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信